Led by ElevateBio’s Finer, LifeEDIT is pursuing novel enzymes for gene editing

LifeEDIT debuted with undisclosed funding from ElevateBio and former parent company AgBiome this week to develop novel RNA-guided nucleases and base editors that could offer broader genome access than existing genome editing enzymes. 

With access to ElevateBio’s gene and cell therapy processing and manufacturing resources, the company plans to both develop an internal pipeline and therapies with partners including fellow ElevateBio portfolio companies. ...